Publications by authors named "Pierre Wijermans"

Claim this Profile
M
MRD Assessment in Patients With Acute Myeloid Leukemia Aged ≥ 60 Years Treated With a 10-Day Decitabine Schedule Versus Intensive Chemotherapy in the AML21 Study.
Adriano Venditti, Michal Kicinski, Ernesta Audisio, Mario Luppi, Monia Lunghi, Pierre Wijermans

Am J Hematol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Decitabine in older patients with AML: quality of life results of the EORTC-GIMEMA-GMDS-SG randomized phase 3 trial.
Fabio Efficace, Michal Kicinski, Corneel Coens, Stefan Suciu, Walter J F M van der Velden, Pierre W Wijermans

Blood· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
1
10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial.
Michael Lübbert, Pierre W Wijermans, Michal Kicinski, Sylvain Chantepie, Walter J F M Van der Velden

Lancet Haematol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia.
Heiko Becker, Dietmar Pfeifer, Gabriele Ihorst, Milena Pantic, Julius Wehrle, Pierre W Wijermans

Ann Hematol· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Distinct bone marrow morphologic features discriminate myelodysplastic syndromes patients with and without an early platelet response to decitabine.
Annette M May, Julia Stomper, Tina E Joeckel, Peter Bronsert, Pierre W Wijermans

Br J Haematol· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
1
10-day vs 5-day decitabine: equivalence cannot be concluded.
Gerwin Huls, Stefan Suciu, Pierre Wijermans, Michal Kicinski, Michael Lübbert

Lancet Haematol· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fetal hemoglobin induction during decitabine treatment of elderly patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: a potential dynamic biomarker of outcome.
Julia Stomper, Gabriele Ihorst, Stefan Suciu, Philipp N Sander, Heiko Becker, Pierre W Wijermans

Haematologica· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Graft-Versus-Leukemia Effect of Allogeneic Stem-Cell Transplantation and Minimal Residual Disease in Patients With Acute Myeloid Leukemia in First Complete Remission.
Jurjen Versluis, Burak Kalin, Wendelien Zeijlemaker, Jakob Passweg, Carlos Graux, Pierre W Wijermans

JCO Precis Oncol· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized controlled trial on the effects of a supervised high intensity exercise program in patients with a hematologic malignancy treated with autologous stem cell transplantation: Results from the EXIST study.
Saskia Persoon, Mai J M ChinAPaw, Laurien M Buffart, Roberto D K Liu, Pierre Wijermans

PLoS One· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic array as compared to karyotyping in myelodysplastic syndromes in a prospective clinical trial.
Marian J Stevens-Kroef, Daniel Olde Weghuis, Najat ElIdrissi-Zaynoun, Bert van der Reijden, Eline M P Cremers, Pierre Wijermans

Genes Chromosomes Cancer· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Implementation of erythroid lineage analysis by flow cytometry in diagnostic models for myelodysplastic syndromes.
Eline M P Cremers, Theresia M Westers, Canan Alhan, Claudia Cali, Heleen A Visser-Wisselaar, Pierre W Wijermans

Haematologica· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elevated fetal haemoglobin is a predictor of better outcome in MDS/AML patients receiving 5-aza-2'-deoxycytidine (Decitabine).
Michael Lübbert, Gabriele Ihorst, Philipp N Sander, Ljudmila Bogatyreva, Heiko Becker, Pierre W Wijermans

Br J Haematol· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma.
Annemiek Broijl, Marie-José Kersten, Wendimagegn Ghidey Alemayehu, Mark-David Levin, Okke de Weerdt, Pierre W Wijermans

Haematologica· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group.
Michael Lübbert, Stefan Suciu, Anne Hagemeijer, Björn Rüter, Uwe Platzbecker, Pierre W Wijermans

Ann Hematol· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Decitabine versus best supportive care in older patients with refractory anemia with excess blasts in transformation (RAEBt) - results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group (GMDSSG).
Heiko Becker, Stefan Suciu, Björn Hans Rüter, Uwe Platzbecker, Aristoteles Giagounidis, Pierre W Wijermans

Ann Hematol· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extended follow up of high-dose melphalan and autologous stem cell transplantation after vincristine, doxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase II HOVON-41 study by the Dutch-Belgian Co-operative Trial Group for Hematology Oncology.
Bouke P C Hazenberg, Alexandra Croockewit, Bronno van der Holt, Sonja Zweegman, Gerard M J Bos, Pierre W Wijermans

Haematologica· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Results of Hypomethylating Agents in AML Treatment.
Marjan Cruijsen, Michael Lübbert, Pierre Wijermans, Gerwin Huls

J Clin Med· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The efficiency of therapeutic erythrocytapheresis compared to phlebotomy: a mathematical tool for predicting response in hereditary hemochromatosis, polycythemia vera, and secondary erythrocytosis.
Dorothea Evers, Jean-Louis Kerkhoffs, Liane Van Egmond, Martin R Schipperus, Pierre W Wijermans

J Clin Apher· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study.
Fortunato Morabito, Sara Bringhen, Alessandra Larocca, Pierre Wijermans, Maria Victoria Mateos

Am J Hematol· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial.
Christof Scheid, Pieter Sonneveld, Ingo G H Schmidt-Wolf, Bronno van der Holt, Laila el Jarari, Pierre Wijermans

Haematologica· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.
Monique Terwijn, Wim L J van Putten, Angèle Kelder, Vincent H J van der Velden, Rik A Brooimans, Pierre Wijermans

J Clin Oncol· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials.
Sara Bringhen, Maria Victoria Mateos, Sonja Zweegman, Alessandra Larocca, Antonietta Pia Falcone, Pierre Wijermans

Haematologica· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma.
Peter M Voorhees, Robert F Manges, Pieter Sonneveld, Sundar Jagannath, George Somlo, Pierre W Wijermans

Br J Haematol· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials.
Antonio Palumbo, Anders Waage, Cyrille Hulin, Meral Beksac, Sonja Zweegman, Pierre Wijermans

Haematologica· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK).
Gert J Ossenkoppele, Georg Stussi, Johan Maertens, Kees van Montfort, Bart J Biemond, Pierre Wijermans

Blood· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis